Thursday, December 28, 2023 1:35:05 PM
LC,
Thanks for posting, but this sounds like another rumor to me. I ran it through the detector 😶 …
“This statement is composed of greater than 99% baseless innuendo for the following reasons:
1. **Speculative and Suggestive**: The statement is purely speculative, suggesting a scenario ("Powers could agree to provide L at cost") without any evidence or context to substantiate the claim.
2. **Implied Wrongdoing**: By saying "if you catch my drift," the statement implies wrongdoing or unethical behavior without directly stating it, which is characteristic of innuendo.
3. **Lack of Transparency Claim**: The assertion that "she's never shared a thing about the numbers with retail" is presented without evidence. It's important to note that companies have various regulatory and legal obligations regarding financial disclosures.
4. **Assumption of Malintent**: The statement assumes malintent on the part of Powers without providing factual support for such a claim.
The statement can also be considered potentially defamatory because it implies unethical or dishonest behavior on the part of Powers without providing any evidence. Defamation involves making false statements that harm someone's reputation. By suggesting improper conduct in a business setting without factual backing, the statement risks defaming Powers, especially if these insinuations are baseless and if Powers is a recognizable figure associated with a specific company or context. Such accusations, when unsubstantiated, can damage a person's professional reputation and credibility.
In summary, the statement relies on innuendo and speculation, lacking factual basis and unfairly implying wrongdoing without substantiation.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
Thanks for posting, but this sounds like another rumor to me. I ran it through the detector 😶 …
“This statement is composed of greater than 99% baseless innuendo for the following reasons:
1. **Speculative and Suggestive**: The statement is purely speculative, suggesting a scenario ("Powers could agree to provide L at cost") without any evidence or context to substantiate the claim.
2. **Implied Wrongdoing**: By saying "if you catch my drift," the statement implies wrongdoing or unethical behavior without directly stating it, which is characteristic of innuendo.
3. **Lack of Transparency Claim**: The assertion that "she's never shared a thing about the numbers with retail" is presented without evidence. It's important to note that companies have various regulatory and legal obligations regarding financial disclosures.
4. **Assumption of Malintent**: The statement assumes malintent on the part of Powers without providing factual support for such a claim.
The statement can also be considered potentially defamatory because it implies unethical or dishonest behavior on the part of Powers without providing any evidence. Defamation involves making false statements that harm someone's reputation. By suggesting improper conduct in a business setting without factual backing, the statement risks defaming Powers, especially if these insinuations are baseless and if Powers is a recognizable figure associated with a specific company or context. Such accusations, when unsubstantiated, can damage a person's professional reputation and credibility.
In summary, the statement relies on innuendo and speculation, lacking factual basis and unfairly implying wrongdoing without substantiation.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
